Ménière's Disease (Adult)

1. Clinical Overview

Summary

Ménière's disease is a chronic disorder of the inner ear characterised by endolymphatic hydrops (excessive endolymph accumulation in the membranous labyrinth), resulting in the classic triad of episodic vertigo, fluctuating sensorineural hearing loss (SNHL), and tinnitus, typically accompanied by aural fullness. Episodes typically last 20 minutes to 12 hours and are separated by symptom-free intervals. [1,2]

The condition usually begins unilaterally but becomes bilateral in 30-47% of patients over 10-20 years. [3] Vertigo attacks tend to "burn out" over time, but progressive hearing loss continues, with approximately 50% of patients developing severe bilateral hearing loss. [4]

Diagnosis is clinical, based on AAO-HNS (American Academy of Otolaryngology–Head and Neck Surgery) diagnostic criteria combined with audiometric confirmation of low-to-medium frequency SNHL. [5] Management is stepwise: dietary modification and betahistine for prophylaxis, vestibular sedatives for acute attacks, and escalation to intratympanic therapy or surgery for refractory disease. [6]

Key Facts

Clinical Pearls

"Triad + Time = Ménière's": The diagnosis hinges on BOTH the symptom triad AND episodic pattern lasting 20 minutes to 12 hours. Seconds = BPPV. Days = labyrinthitis. Constant = central pathology.

"Low-Frequency Loss First": Early Ménière's preferentially affects low frequencies (250-1000 Hz) on audiometry—hearing loss is fluctuating initially, then becomes permanent.

"Betahistine for Prevention, NOT Acute Attacks": Betahistine (histamine H1/H3 analogue) is used for long-term prophylaxis. Acute attacks require vestibular sedatives (prochlorperazine/cyclizine), but avoid prolonged use (delays vestibular compensation).

"Rule Out Acoustic Neuroma": ANY unilateral SNHL warrants MRI of internal auditory meati (IAMs) to exclude vestibular schwannoma—audiometric patterns may overlap.

"Tumarkin Attacks = Drop Without Warning": ~5% of patients develop sudden falls without loss of consciousness ("otolithic crisis")—high injury risk, may require ablative therapy.

---

2. Epidemiology

Incidence and Prevalence

Demographics and Risk Factors

Established Risk Factors:

• Family History: 8-15% have first-degree relative with Ménière's disease (suggests genetic susceptibility) [9]
• Autoimmune Disorders: Association with autoimmune inner ear disease, SLE, rheumatoid arthritis [10]
• Migraine: Co-occurrence in 43-56% (shared vascular/neural mechanisms) [11]
• Allergies: Conflicting evidence; some studies suggest association with atopy [12]

Ethnicity Variations:

• Higher incidence in Northern European populations (50/100,000) vs. Asian populations (15/100,000) [7]
• Lower incidence in children and adolescents (less than 5% of all cases)

Natural History:

• Early Stage (0-5 years): Predominantly episodic vertigo, fluctuating hearing loss
• Middle Stage (5-15 years): Decreased vertigo frequency, progressive permanent hearing loss
• Late Stage (> 15 years): "Burnt-out" Ménière's—vertigo rare, bilateral severe SNHL common

Exam Detail: Viva Question: "Why does Ménière's disease predominantly affect middle-aged adults?"

Model Answer: "The exact mechanism is unknown, but endolymphatic hydrops develops over years through gradual dysfunction of endolymph absorption in the endolymphatic sac. This cumulative pathophysiology explains the peak onset in the 5th-6th decades. Additionally, age-related vascular changes and immune dysregulation may contribute. Rare early-onset cases (less than 20 years) often have autoimmune or genetic predisposition."

---

3. Aetiology and Pathophysiology

Endolymphatic Hydrops: The Central Pathophysiology

Ménière's disease = Clinical syndrome of endolymphatic hydrops, though not all hydrops causes Ménière's symptoms. [1,2]

Normal Inner Ear Fluid Dynamics

• Endolymph Production: Stria vascularis (cochlea) and dark cells (vestibule)
• Endolymph Absorption: Endolymphatic sac (in posterior petrous bone)

Pathophysiology of Endolymphatic Hydrops

Proposed Mechanisms:

1. Reduced Endolymph Absorption (most accepted theory)

   • Endolymphatic sac dysfunction → impaired resorption
   • Causes: Autoimmune inflammation, fibrosis, genetic abnormalities, viral injury [13]

2. Increased Endolymph Production

   • Stria vascularis hyperactivity (less evidence)

3. Vascular Hypothesis

   • Vasospasm or ischaemia of labyrinthine vessels → ionic imbalance [11]

Consequences of Hydrops:

┌──────────────────────────────────────────────────────────┐
│   ENDOLYMPHATIC HYDROPS PATHOPHYSIOLOGY                  │
├──────────────────────────────────────────────────────────┤
│                                                          │
│  NORMAL STATE:                                            │
│  • Endolymph volume regulated by production/absorption   │
│  • High K⁺ endolymph separated from perilymph by         │
│    Reissner's membrane (cochlea) and vestibular          │
│    membranes                                             │
│                                                          │
│  MÉNIÈRE'S (HYDROPS):                                     │
│  • Endolymph accumulation → distension of membranous     │
│    labyrinth                                             │
│  • Increased pressure stretches Reissner's membrane      │
│                                                          │
│  DURING ATTACK:                                           │
│  • Membrane rupture → mixing of K⁺-rich endolymph with   │
│    Na⁺-rich perilymph                                    │
│  • K⁺ intoxication of vestibular nerve → VERTIGO         │
│  • K⁺ intoxication of cochlear nerve → HEARING LOSS      │
│  • Pressure on tympanic membrane → AURAL FULLNESS        │
│                                                          │
│  AFTER ATTACK:                                            │
│  • Membrane heals → symptoms resolve                     │
│  • Repeated ruptures → permanent hair cell damage →      │
│    progressive SNHL                                      │
│                                                          │
└──────────────────────────────────────────────────────────┘

Histopathological Features

Temporal Bone Studies (Autopsy/Surgical Specimens): [14]

• Distension of cochlear duct (bowing of Reissner's membrane into scala vestibuli)
• Saccular and utricular hydrops
• Degeneration of sensory hair cells (organ of Corti, vestibular maculae)
• Atrophy of stria vascularis
• Endolymphatic sac fibrosis/hypoplasia

Why Episodic?

Rupture-Repair Cycle Hypothesis: [2]

1. Endolymph accumulates → pressure builds
2. Reissner's membrane ruptures → fluid mixing → symptoms
3. Membrane heals → symptoms resolve
4. Cycle repeats → progressive hair cell death → permanent hearing loss

Aetiological Theories

Idiopathic Ménière's Disease (majority of cases):

• No clear precipitant
• Likely multifactorial: genetic susceptibility + environmental triggers

Secondary Endolymphatic Hydrops (mimics Ménière's):

• Post-traumatic (temporal bone fracture)
• Post-infectious (labyrinthitis, syphilis)
• Autoimmune inner ear disease
• Otosclerosis affecting otic capsule

Exam Detail: Viva Question: "Explain why vertigo attacks in Ménière's disease last 20 minutes to 12 hours, whereas BPPV lasts seconds."

Model Answer: "In Ménière's disease, vertigo results from endolymphatic membrane rupture, allowing mixing of endolymph (high K⁺) with perilymph (low K⁺). This causes potassium intoxication of the vestibular nerve, triggering sustained vertigo. The episode lasts until the membrane heals and ionic gradients are restored—typically 20 minutes to 12 hours.

In contrast, BPPV is caused by otoconia displaced into semicircular canals. Vertigo occurs only during head movement as the otoconia shift, stimulating cupular deflection. When the head is stationary, the otoconia settle and vertigo stops within seconds. This is a mechanical, position-dependent process rather than a biochemical disturbance."

---

4. Clinical Presentation

Classic Ménière's Episode

The "Attack" Pattern:

Symptom Tetrad

1. Episodic Vertigo

• Character: Rotational/spinning (patient or environment)
• Severity: Prostrating—patients unable to stand, require bed rest
• Duration: 20 minutes to 12 hours (median 2-4 hours)
• Frequency: Highly variable (daily to once per year)
• Triggers: Often unpredictable; some report stress, sleep deprivation, dietary salt, caffeine
• Associated Features: Nausea, vomiting, diaphoresis, pallor (autonomic activation)

NOT Ménière's if:

• Vertigo less than 20 minutes (consider BPPV, TIA)
• Vertigo > 24 hours (consider labyrinthitis, vestibular neuronitis, stroke)
• Constant vertigo (central pathology)

2. Fluctuating Sensorineural Hearing Loss

• Pattern: Initially fluctuates (improves between attacks), later becomes permanent
• Frequency Affected: Low-to-medium frequencies (250-1000 Hz) affected first [5]
• Laterality: Unilateral at onset (30-47% become bilateral over years)
• Perception: "Muffled" or "distorted" sound, difficulty with speech discrimination
• Natural History: Progressive over years → eventually flat or pantonal loss

3. Tinnitus

• Character: Low-pitched roaring, humming, buzzing (vs. high-pitched in presbycusis/noise-induced)
• Pattern: Fluctuates with attacks (worsens during prodrome/attack)
• Laterality: Ipsilateral to affected ear
• Impact: May become constant in late disease

4. Aural Fullness (Ear Pressure)

• Description: "Blocked ear," "underwater," "pressure in ear"
• Timing: Often prodromal symptom (predicts impending attack)
• Laterality: Ipsilateral to affected ear
• Mechanism: Distension of membranous labyrinth

Special Presentations

Tumarkin Attacks ("Otolithic Crisis")

• Occurrence: ~5% of Ménière's patients [15]
• Presentation: Sudden drop to ground without warning or loss of consciousness
• Mechanism: Sudden stimulation of otolithic organs (saccule/utricle) → loss of postural tone
• Differential: Distinguish from syncope (no prodrome, no LOC, immediate recovery)
• Significance: High risk of injury—may require ablative therapy (intratympanic gentamicin, labyrinthectomy)

Lermoyez Syndrome (Variant)

• Pattern: Hearing improves DURING or AFTER vertigo attack (opposite of typical Ménière's)
• Theory: Vertigo caused by vascular spasm; vasodilation after attack improves cochlear perfusion
• Rarity: Uncommon variant

"Burnt-Out" Ménière's Disease

• Stage: Late disease (> 15 years)
• Features: Vertigo attacks cease or become rare, bilateral severe SNHL, persistent tinnitus, chronic imbalance
• Mechanism: Permanent destruction of vestibular apparatus ("auto-ablation")

Natural History and Disease Progression

Stage 1 (Early, 0-5 years):

• Episodic vertigo (main complaint)
• Fluctuating hearing loss (recovers between attacks)
• Intermittent tinnitus

Stage 2 (Intermediate, 5-15 years):

• Vertigo attacks persist but may decrease in frequency
• Hearing loss becomes more persistent (less recovery between attacks)
• Tinnitus more constant

Stage 3 (Late, > 15 years):

• "Burnt-out" disease: vertigo rare or absent
• Bilateral severe SNHL (50% of cases)
• Chronic tinnitus, chronic imbalance

---

5. Clinical Examination

General Inspection

During Acute Attack:

• Patient prefers to lie still (movement exacerbates symptoms)
• Nystagmus present (see below)
• Autonomic features: pallor, sweating, vomiting
• Unable to walk or stand (severe disequilibrium)

Between Attacks (Interictal):

• May appear entirely normal
• May have subtle gait imbalance in late disease

Otoscopy

• Tympanic Membrane: Normal (Ménière's is inner ear pathology)
• External Auditory Canal: Normal

Key Differential: Otoscopy helps exclude chronic otitis media or cholesteatoma as cause of hearing loss.

Nystagmus Assessment

During Acute Attack:

• Character: Horizontal with rotatory component (peripheral pattern)
• Fixation: Suppressed by visual fixation (confirms peripheral origin)
• Intensity: Increases with gaze in direction of fast phase (Alexander's law)

Between Attacks:

• Nystagmus usually absent
• May have subtle spontaneous nystagmus in late disease (vestibular paresis)

Tuning Fork Tests (Rinne and Weber)

Affected Ear (assuming unilateral SNHL):

Note: If Weber lateralises to affected ear, consider conductive component (e.g., secondary middle ear effusion).

Romberg Test

• During Attack: Positive (falls with eyes closed)
• Between Attacks: May be normal or subtle imbalance

Gait Assessment

• During Attack: Unable to walk (severe vertigo)
• Between Attacks: May have subtle ataxia in late bilateral disease

Head Impulse Test (HIT)

• Early Disease: Normal (vestibular function preserved between attacks)
• Late Disease: Abnormal (corrective saccade indicates vestibular hypofunction)

Dix-Hallpike Manoeuvre

• Ménière's: Negative (no positional nystagmus/vertigo)
• BPPV: Positive (rotatory nystagmus with latency after head positioning)

Key Differential: If Dix-Hallpike is positive, consider BPPV rather than Ménière's (or co-existing conditions).

Neurological Examination

Red Flags (Suggest Central Pathology, NOT Ménière's):

Exam Detail: OSCE Station: "Examine this patient presenting with episodic vertigo and hearing loss."

Candidate Approach:

1. Introduction: Wash hands, introduce, consent, chaperone
2. General Inspection: Patient comfortable? Nystagmus at rest? Hearing aids?
3. Otoscopy: Examine both ears (exclude middle ear disease)
4. Tuning Fork Tests: Rinne (both sides), Weber
5. Nystagmus Assessment: Look straight ahead, left/right/up/down gaze
6. Dix-Hallpike: Test both sides (exclude BPPV)
7. Romberg Test: Eyes open, then closed
8. Gait: Observe walking, tandem gait
9. Cranial Nerves: CN V, VII, VIII (if time permits)
10. Thank Patient: Offer to perform audiometry, MRI IAMs

Summary Statement: "This 52-year-old presents with episodic vertigo and unilateral hearing loss. Examination reveals a positive Rinne test on the right with Weber lateralising to the left, consistent with right-sided sensorineural hearing loss. Dix-Hallpike is negative. There are no cerebellar signs. The clinical picture is consistent with Ménière's disease. I would like to arrange audiometry and MRI of the internal auditory meati to exclude acoustic neuroma."

---

6. Differential Diagnosis

Key Differentials of Episodic Vertigo

Key Differentials of Unilateral SNHL

MUST exclude:

1. Vestibular Schwannoma (Acoustic Neuroma): MRI IAMs essential for ALL unilateral SNHL
2. Sudden Sensorineural Hearing Loss (SSNHL): Acute (less than 72hr), requires urgent steroids
3. Chronic Otitis Media/Cholesteatoma: Otoscopy abnormal
4. Temporal Bone Trauma: History of head injury

Comparison: Ménière's vs. Vestibular Migraine

Overlap: 43-56% of Ménière's patients have migraine history—shared pathophysiology (neurovascular). [11]

---

7. Investigations

Diagnostic Approach

┌──────────────────────────────────────────────────────────┐
│   MÉNIÈRE'S DISEASE DIAGNOSTIC PATHWAY                   │
├──────────────────────────────────────────────────────────┤
│                                                          │
│  STEP 1: CLINICAL DIAGNOSIS (AAO-HNS 2015 CRITERIA)      │
│  • ≥2 spontaneous vertigo episodes (20 min - 12 hr)      │
│  • Audiometric SNHL (low-to-medium freq) in affected ear │
│  • Fluctuating aural symptoms (hearing/tinnitus/fullness)│
│  • Other causes excluded                                 │
│                                                          │
│  STEP 2: AUDIOMETRY (ESSENTIAL)                           │
│  • Pure tone audiometry → Low-freq SNHL                  │
│  • Speech audiometry → Discrimination scores             │
│  • Tympanometry → Normal (middle ear function intact)    │
│                                                          │
│  STEP 3: MRI IAMs (ESSENTIAL - EXCLUDE ACOUSTIC NEUROMA) │
│  • MRI with gadolinium contrast                          │
│  • Exclude vestibular schwannoma, CPA lesions            │
│                                                          │
│  STEP 4: VESTIBULAR TESTING (SPECIALIST)                  │
│  • Caloric testing → Reduced response on affected side   │
│  • Video head impulse test (vHIT) → Assess VOR           │
│  • Electrocochleography (ECoG) → Elevated SP/AP ratio    │
│                                                          │
│  STEP 5: ADDITIONAL (IF ATYPICAL)                         │
│  • Autoimmune screen (if bilateral/rapid progression)    │
│  • Syphilis serology (if risk factors)                   │
│  • Thyroid function (associated autoimmune disease)      │
│                                                          │
└──────────────────────────────────────────────────────────┘

AAO-HNS Diagnostic Criteria (2015) [5]

Definite Ménière's Disease requires ALL of:

1. ≥2 spontaneous episodes of vertigo, each lasting 20 minutes to 12 hours
2. Audiometrically documented low-to-medium frequency sensorineural hearing loss in the affected ear on at least one occasion before, during, or after a vertigo episode
3. Fluctuating aural symptoms (hearing loss, tinnitus, or fullness) in the affected ear
4. Other causes excluded (e.g., vestibular schwannoma, labyrinthitis, stroke)

Probable Ménière's Disease requires:

• ≥2 episodes of vertigo or dizziness (20 min - 24 hr)
• Fluctuating aural symptoms in affected ear
• Other causes excluded

Note: Audiometric confirmation upgrades "probable" to "definite."

Audiometry (Essential)

Pure Tone Audiometry (PTA)

Classic Ménière's Pattern:

Key Features:

• Unilateral at onset (30-47% become bilateral)
• Sensorineural pattern (air conduction = bone conduction, both reduced)
• Discrimination scores may be disproportionately poor (cochlear distortion)

Tympanometry

• Normal middle ear function (Type A tympanogram)
• Excludes conductive pathology

Speech Audiometry

• Speech Reception Threshold (SRT): Corresponds to PTA
• Word Recognition Score (WRS): May be reduced (cochlear distortion)

MRI Internal Auditory Meati (IAMs) - ESSENTIAL

Indication: ALL patients with unilateral SNHL require MRI to exclude vestibular schwannoma [16]

Protocol:

• T1-weighted with gadolinium contrast (enhances schwannomas)
• T2-weighted (visualises fluid in IAMs, CPA)
• High-resolution sequences (1-2mm slices)

Expected Finding in Ménière's:

• Normal MRI (no mass, no enhancement)
• May show endolymphatic hydrops on delayed gadolinium-enhanced MRI (specialist protocol) [17]

Differential: If CPA mass present → Vestibular schwannoma, NOT Ménière's.

Vestibular Function Testing (Specialist)

Caloric Testing

• Method: Warm and cold water/air irrigation of external auditory canal → monitors nystagmus response
• Ménière's Finding: Reduced caloric response on affected side (canal paresis)
• Utility: Confirms vestibular hypofunction, lateralises disease

Video Head Impulse Test (vHIT)

• Method: Rapid head rotations while patient fixates on target → measures vestibulo-ocular reflex (VOR)
• Ménière's Finding: Abnormal in late disease (corrective saccades)
• Utility: Assesses peripheral vestibular function

Electrocochleography (ECoG)

• Method: Electrode placed on tympanic membrane or external canal → records cochlear potentials
• Ménière's Finding: Elevated SP/AP ratio (summating potential / action potential > 0.4)
• Sensitivity: 60-70% (not diagnostic alone)
• Utility: Supports diagnosis in uncertain cases

Vestibular Evoked Myogenic Potentials (VEMP)

• Cervical VEMP (cVEMP): Saccular function
• Ocular VEMP (oVEMP): Utricular function
• Ménière's Finding: Reduced amplitude or absent responses

Delayed Gadolinium-Enhanced MRI of Endolymphatic Hydrops

Specialist Investigation (Not Routine):

• Method: IV gadolinium → wait 4 hours → MRI with hydrops-specific sequences [17]
• Finding: Visualises endolymphatic hydrops (distension of scala media)
• Utility: Research tool; clinical diagnosis does not require imaging confirmation of hydrops
• Limitation: Hydrops may be present without Ménière's symptoms (not specific)

Laboratory Investigations (If Atypical Features)

---

8. Management

Overall Approach

Goals:

1. Reduce frequency and severity of vertigo attacks
2. Preserve hearing (where possible)
3. Improve quality of life
4. Manage tinnitus and psychological impact

Stepped Approach:

• Step 1: Lifestyle modification + betahistine
• Step 2: Intratympanic corticosteroids
• Step 3: Intratympanic gentamicin (vestibular ablation)
• Step 4: Surgery (endolymphatic sac decompression, vestibular neurectomy, labyrinthectomy)

Acute Attack Management

Objectives: Relieve vertigo, nausea, vomiting during attack

Non-Pharmacological:

• Rest in quiet, dark room (minimise visual/auditory stimulation)
• Avoid head movements during acute phase
• Hydration (IV fluids if severe vomiting)

CRITICAL: Avoid prolonged use of vestibular sedatives (> 2-3 days)—delays central vestibular compensation. [6]

Prophylactic (Preventive) Treatment

First-Line: Betahistine + Dietary Modification

Betahistine:

Dietary Modification:

Thiazide Diuretics:

• Agent: Bendroflumethiazide 2.5mg OD or Hydrochlorothiazide 25mg OD
• Rationale: Reduce endolymph volume
• Evidence: Limited; some older trials suggest benefit [6]
• Side Effects: Hypokalaemia, postural hypotension, hyperglycaemia
• Use: Consider if betahistine + diet fails; monitor U&E

Second-Line: Intratympanic Corticosteroids

Indication: Failed medical therapy, frequent attacks

Advantage over Gentamicin: Lower risk of hearing loss.

Third-Line: Intratympanic Gentamicin (Vestibular Ablation)

Indication: Refractory vertigo, failed steroids, unilateral disease with poor hearing

Titration Approach: Give single injection → wait 4-6 weeks → assess response → repeat if needed (reduces hearing loss risk).

Surgical Management (Refractory Cases)

Indications: Failed medical and intratympanic therapy, disabling vertigo, unilateral disease

1. Endolymphatic Sac Decompression/Shunt

2. Vestibular Neurectomy

3. Labyrinthectomy

Non-Invasive Devices

Meniett Device (Positive Pressure Therapy)

Vestibular Rehabilitation Therapy (VRT)

Indication: All patients, especially after ablative therapy

Hearing Rehabilitation

Hearing Aids:

• Indicated when hearing loss impacts communication
• Digital hearing aids with frequency-specific amplification

Cochlear Implantation:

• Considered for bilateral profound SNHL (late "burnt-out" Ménière's)
• Evidence: Good outcomes in selected patients [24]

Psychological Support

• Counselling: Address anxiety, depression (common in Ménière's)
• Cognitive Behavioural Therapy (CBT): For tinnitus management
• Support Groups: Ménière's Society (UK), Vestibular Disorders Association (USA)

Summary Algorithm

┌──────────────────────────────────────────────────────────┐
│   MÉNIÈRE'S DISEASE MANAGEMENT ALGORITHM                 │
├──────────────────────────────────────────────────────────┤
│                                                          │
│  ACUTE ATTACK:                                            │
│  • Prochlorperazine 3-6mg buccal PRN                     │
│  • Rest in quiet, dark room                              │
│  • Short course only (avoid prolonged vestibular         │
│    sedation)                                             │
│                                                          │
│  ↓                                                        │
│                                                          │
│  FIRST-LINE PROPHYLAXIS:                                  │
│  • Betahistine 16mg TDS (3-6 month trial)                │
│  • Low-salt diet (less than 2g sodium/day)                        │
│  • Caffeine and alcohol reduction                        │
│  • Stress management                                     │
│                                                          │
│  ↓ (If inadequate control)                               │
│                                                          │
│  CONSIDER THIAZIDE DIURETIC:                              │
│  • Bendroflumethiazide 2.5mg OD                          │
│  • Monitor U&E                                           │
│                                                          │
│  ↓ (If refractory - specialist referral)                 │
│                                                          │
│  INTRATYMPANIC CORTICOSTEROIDS:                           │
│  • Dexamethasone injections (3-4 over 2-4 weeks)         │
│  • 60-80% response rate                                  │
│  • Preserves hearing                                     │
│                                                          │
│  ↓ (If still refractory)                                 │
│                                                          │
│  INTRATYMPANIC GENTAMICIN:                                │
│  • Vestibular ablation                                   │
│  • 80-95% vertigo control                                │
│  • Risk: 10-30% hearing loss                             │
│  • Contraindicated in bilateral disease                  │
│                                                          │
│  ↓ (If failed)                                           │
│                                                          │
│  SURGERY (Selected Cases):                                │
│  • Vestibular neurectomy (if serviceable hearing)        │
│  • Labyrinthectomy (if non-serviceable hearing)          │
│  • Endolymphatic sac decompression (controversial)       │
│                                                          │
│  ADJUNCTS (All Stages):                                   │
│  • Vestibular rehabilitation therapy (VRT)               │
│  • Hearing aids (if indicated)                           │
│  • Psychological support (anxiety, depression)           │
│  • Tinnitus management (CBT, sound therapy)              │
│                                                          │
└──────────────────────────────────────────────────────────┘

---

9. Complications

Complications of the Disease

Complications of Treatment

Intratympanic Gentamicin:

• Sensorineural Hearing Loss: 10-30% (cochlear toxicity)
• Complete Vestibular Loss: Intended effect, but may cause chronic imbalance
• Tympanic Membrane Perforation: Usually heals; rarely persistent

Surgical Complications:

Vestibular Sedatives (Prolonged Use):

• Delayed Vestibular Compensation: Chronic imbalance
• Sedation, Falls (especially elderly)
• Dependency (benzodiazepines)

---

10. Prognosis and Outcomes

Natural History

Vertigo:

• Early Disease: Frequent, severe attacks
• Middle Disease: Attacks may persist but often decrease in frequency
• Late Disease (> 15 years): "Burnt-out"—vertigo attacks rare or absent (50-70% of patients)

Mechanism of "Burn-Out": Progressive destruction of vestibular hair cells → auto-ablation

Hearing:

• Invariably progressive over years
• Bilateral SNHL: Develops in 30-47% (median time 10-15 years)
• Severe Bilateral Loss: ~50% of bilateral cases → hearing aid/cochlear implant candidates

Functional Outcomes

Factors Associated with Poor Prognosis

• Bilateral disease (worse hearing outcomes)
• Frequent attacks (> 10 per year)
• Young age at onset (less than 40 years) → longer disease duration
• Family history (genetic predisposition)

Mortality

• No direct mortality from Ménière's disease
• Indirect risks: Injury from falls (especially Tumarkin attacks), drowning (attacks during swimming)

---

11. Evidence and Guidelines

Key Guidelines

1. AAO-HNS Clinical Practice Guideline: Ménière's Disease (2020) [5]

   • Diagnostic criteria (2015 update)
   • Management recommendations
   • Evidence-based treatment algorithm

2. NICE Clinical Knowledge Summaries: Ménière's Disease [6]

   • UK primary care guidance
   • When to refer to ENT
   • First-line management (betahistine, dietary modification)

3. American Academy of Neurology: Vestibular Disorders [23]

   • Vestibular rehabilitation therapy recommendations

Key Evidence

Betahistine (Prophylaxis)

Cochrane Review (2023): [18]

• Conclusion: "Limited high-quality evidence for betahistine in Ménière's disease. Some trials show benefit in reducing vertigo frequency, but evidence is low certainty due to small sample sizes and heterogeneity."
• Clinical Practice: Widely used as first-line due to excellent safety profile and some positive trials
• Mechanism: H1 agonist/H3 antagonist → improves inner ear microcirculation

Intratympanic Gentamicin

Systematic Reviews: [20]

• Vertigo Control: 80-95% complete or substantial control
• Hearing Risk: 10-30% further hearing loss
• Dosing Strategy: Titrated (single injection → wait → reassess) reduces hearing loss vs. fixed protocols

Intratympanic Corticosteroids

Meta-analyses: [19]

• Vertigo Control: 60-80% improvement
• Hearing Preservation: Better than gentamicin
• Mechanism: Anti-inflammatory, may reduce endolymphatic hydrops

Vestibular Rehabilitation

Cochrane Review: [23]

• Conclusion: "Moderate-quality evidence that vestibular rehabilitation improves balance and reduces chronic dizziness in peripheral vestibular disorders."
• Application: Particularly effective after ablative therapy (gentamicin, surgery)

Endolymphatic Sac Surgery

Controversy: [21]

• Historical Use: Common in 1980s-1990s
• Placebo-Controlled Trials: Showed no significant difference vs. sham surgery
• Current Use: Declined in favour of intratympanic therapy; some centres still offer

---

12. Examination Focus

Viva Questions and Model Answers

Question 1: "What is Ménière's disease?"

Model Answer: "Ménière's disease is a chronic disorder of the inner ear characterised by endolymphatic hydrops—excessive accumulation of endolymph in the membranous labyrinth. It presents with a classic tetrad of episodic vertigo, fluctuating sensorineural hearing loss, tinnitus, and aural fullness. Episodes last 20 minutes to 12 hours, separated by symptom-free intervals. The disease typically begins unilaterally but becomes bilateral in 30-47% of cases over 10-20 years. The underlying cause is unknown in most cases (idiopathic), but it may relate to endolymphatic sac dysfunction, autoimmune mechanisms, or vascular disturbances."

---

Question 2: "Explain the pathophysiology of vertigo in Ménière's disease."

Model Answer: "The pathophysiology involves endolymphatic hydrops—accumulation of endolymph due to impaired absorption by the endolymphatic sac. This causes distension of the membranous labyrinth and stretching of Reissner's membrane in the cochlea and vestibular membranes. During an attack, these membranes rupture, allowing high-potassium endolymph to mix with low-potassium perilymph. This potassium intoxication of the vestibular nerve triggers intense vertigo. The symptoms resolve when the membranes heal and ionic gradients are restored. However, repeated rupture-repair cycles cause progressive damage to sensory hair cells, leading to permanent hearing loss and eventual vestibular 'burn-out' in late disease."

---

Question 3: "How do you differentiate Ménière's disease from BPPV?"

Model Answer:

"Clinically, the key differentiator is episode duration: BPPV lasts seconds and is triggered by head movement, whereas Ménière's lasts 20 minutes to hours and is spontaneous. Additionally, BPPV has no hearing loss or tinnitus."

---

Question 4: "What are the AAO-HNS diagnostic criteria for Ménière's disease?"

Model Answer: "The AAO-HNS 2015 criteria for definite Ménière's disease require:

1. Two or more spontaneous episodes of vertigo, each lasting 20 minutes to 12 hours
2. Audiometrically documented low-to-medium frequency sensorineural hearing loss in the affected ear on at least one occasion before, during, or after a vertigo episode
3. Fluctuating aural symptoms (hearing loss, tinnitus, or fullness) in the affected ear
4. Other causes excluded (e.g., vestibular schwannoma via MRI)

Probable Ménière's is diagnosed if criteria are met but without audiometric confirmation."

---

Question 5: "Why is MRI essential in unilateral sensorineural hearing loss?"

Model Answer: "MRI of the internal auditory meati with gadolinium contrast is essential to exclude vestibular schwannoma (acoustic neuroma), which can present with progressive unilateral SNHL, tinnitus, and imbalance—clinically overlapping with Ménière's disease. Vestibular schwannomas are benign tumours arising from the Schwann cells of the vestibular nerve, typically in the cerebellopontine angle. They enhance with gadolinium on MRI. Missing this diagnosis can lead to tumour growth, brainstem compression, and surgical complications. Therefore, MRI is mandatory for all patients presenting with unilateral SNHL."

---

Question 6: "Describe the management of an acute Ménière's attack."

Model Answer: "Acute management aims to relieve vertigo and nausea:

Pharmacological:

• Prochlorperazine 3-6mg buccal or 12.5mg IM (if vomiting prevents oral)—vestibular sedative and antiemetic
• Cyclizine 50mg PO/IM as an alternative
• Ondansetron 4-8mg for severe vomiting

Non-Pharmacological:

• Rest in a quiet, dark room (minimise visual/auditory stimulation)
• Avoid head movements during acute phase
• IV fluids if severe vomiting causes dehydration

Critical Point: Use vestibular sedatives for short courses only (2-3 days maximum) because prolonged use delays central vestibular compensation, leading to chronic imbalance."

---

Question 7: "What is the evidence for betahistine in Ménière's disease?"

Model Answer: "Betahistine is a histamine H1 receptor agonist and H3 receptor antagonist that is thought to improve inner ear microcirculation and reduce endolymphatic pressure. It is widely used as first-line prophylaxis at a dose of 16mg three times daily.

Evidence: A 2023 Cochrane systematic review found limited high-quality evidence due to small, heterogeneous trials. Some studies show reduction in vertigo frequency, but the evidence certainty is low. However, betahistine has an excellent safety profile (side effects: mild dyspepsia, headache), and clinical guidelines (NICE, AAO-HNS) recommend a 3-6 month trial.

Clinical Practice: Despite limited robust evidence, betahistine remains first-line because it is safe, well-tolerated, and some patients report benefit."

---

Question 8: "When would you refer for intratympanic gentamicin therapy?"

Model Answer: "Intratympanic gentamicin is considered for refractory Ménière's disease when:

Indications:

1. Frequent disabling vertigo attacks despite optimal medical therapy (betahistine, dietary modification, diuretics)
2. Failed intratympanic corticosteroids
3. Unilateral disease (contraindicated in bilateral disease)
4. Poor or non-serviceable hearing in the affected ear (reduces risk of significant hearing loss)

Mechanism: Gentamicin is ototoxic—selectively destroys vestibular hair cells (chemical labyrinthectomy) → abolishes vertigo attacks.

Outcomes: 80-95% vertigo control.

Risks: 10-30% risk of further sensorineural hearing loss, chronic imbalance requiring vestibular rehabilitation.

Contraindication: Bilateral Ménière's (risk of bilateral vestibular loss → oscillopsia, severe imbalance)."

---

Question 9: "What are Tumarkin attacks and how are they managed?"

Model Answer: "Tumarkin attacks, or otolithic crises, are sudden drop attacks occurring in ~5% of Ménière's patients. The patient suddenly falls to the ground without warning or loss of consciousness, believed to be caused by sudden stimulation of otolithic organs (saccule/utricle), leading to transient loss of postural tone.

Clinical Features:

• Sudden fall ("dropped like a stone")
• No prodrome
• No loss of consciousness
• Immediate recovery (can stand up immediately)
• High risk of injury (fractures, head trauma)

Differential: Syncope (has prodrome, LOC), epilepsy (LOC, post-ictal confusion).

Management:

• Warn patient of injury risk
• Avoid high-risk activities (driving, heights, ladders)
• Ablative therapy if recurrent:
  • Intratympanic gentamicin (first-line)
  • Labyrinthectomy (if non-serviceable hearing)
  • Vestibular neurectomy (if serviceable hearing)

Goal: Eliminate vestibular input from diseased ear to prevent further attacks."

---

Question 10: "What is the prognosis for hearing in Ménière's disease?"

Model Answer: "Hearing prognosis in Ménière's disease is generally poor—progressive sensorineural hearing loss is inevitable in most patients.

Natural History:

• Early: Fluctuating low-frequency SNHL (recovers between attacks)
• Middle: Less fluctuation, progressive loss affecting mid-high frequencies
• Late: Permanent pantonal severe SNHL

Bilateral Disease: 30-47% develop contralateral involvement over 10-20 years.

Severe Bilateral Loss: ~50% of bilateral cases → candidates for hearing aids or cochlear implantation.

Serviceable Hearing: ~50% maintain serviceable hearing in at least one ear with conservative management.

Treatment Impact: Intratympanic gentamicin carries 10-30% risk of further hearing loss, whereas intratympanic steroids and vestibular rehabilitation have minimal hearing risk. Labyrinthectomy causes complete hearing loss in the operated ear (reserved for non-serviceable hearing)."

---

13. Patient/Layperson Explanation

What is Ménière's Disease?

Ménière's disease is a condition affecting the inner ear that causes episodes of severe dizziness (vertigo), hearing loss, ringing in the ear (tinnitus), and a feeling of fullness or pressure in the ear.

What Causes It?

The inner ear contains fluid that helps with balance and hearing. In Ménière's disease, too much fluid builds up in the inner ear (called "endolymphatic hydrops"). This extra fluid causes pressure, and sometimes the delicate membranes in the ear burst, releasing the fluid and triggering symptoms. The exact reason why this happens is not fully understood, but it may be related to immune system problems, genetics, or blood flow issues in the ear.

What Are the Symptoms?

During an attack, you may experience:

• Severe spinning dizziness (vertigo): The room spins around you, and you may feel very sick (nausea and vomiting). You may need to lie down and stay still.
• Hearing loss: Your hearing may become muffled or distorted, especially for low-pitched sounds. This usually affects one ear.
• Ringing or buzzing in the ear (tinnitus): Often described as a roaring or humming sound.
• Fullness in the ear: A sensation of pressure or blockage in the affected ear.

How long do attacks last? Attacks typically last between 20 minutes and 12 hours (usually 2-4 hours). Between attacks, you may feel completely normal, although some people have ongoing tinnitus or hearing loss.

How often do attacks happen? This varies greatly—some people have attacks every few days, while others have them only a few times a year.

Will It Get Worse?

Ménière's disease is unpredictable:

• Vertigo attacks often become less frequent over time (the disease "burns out"), but this can take many years.
• Hearing loss tends to get gradually worse over the years. In some people, both ears become affected.

How is it Diagnosed?

Your doctor will:

• Ask about your symptoms (especially the pattern of vertigo, hearing loss, and tinnitus)
• Perform a hearing test (audiometry) to check for hearing loss
• Arrange an MRI scan of the brain to rule out other causes like a tumour on the hearing nerve

How is it Treated?

There is no cure for Ménière's disease, but treatments can help control symptoms:

During an attack:

• Anti-sickness tablets (e.g., prochlorperazine) to relieve dizziness and nausea
• Rest in a quiet, dark room
• Avoid sudden head movements

To prevent attacks:

• Betahistine tablets: A medication that may reduce the frequency of attacks (taken long-term)
• Low-salt diet: Reducing salt intake (less than 2 grams of sodium per day) may help reduce fluid build-up in the ear
• Reduce caffeine and alcohol: These may trigger attacks in some people
• Stress management: Stress can sometimes trigger attacks

If these don't work:

• Injections into the ear: Steroid or gentamicin injections may be offered by a specialist
• Surgery: In severe cases, surgery may be considered to control vertigo

Hearing aids: If hearing loss becomes significant, hearing aids can help.

What About Driving?

You must inform the DVLA (UK) if you have Ménière's disease, as sudden vertigo attacks can make driving dangerous. You may need to stop driving temporarily or permanently, depending on the frequency of your attacks.

What's the Outlook?

Most people can manage Ménière's disease with medication and lifestyle changes. Vertigo attacks often become less frequent over time, but hearing loss usually gets gradually worse. About 1 in 3 people will eventually have symptoms in both ears.

Where Can I Get Support?

• Ménière's Society (UK): menieres.org.uk
• Vestibular Disorders Association (USA): vestibular.org

---

14. References

Primary Guidelines

1. Basura GJ, Adams ME, Monfared A, et al. Clinical Practice Guideline: Ménière's Disease. Otolaryngol Head Neck Surg. 2020;162(2_suppl):S1-S55. doi:10.1177/0194599820909438 PMID: 32267799

2. Nakashima T, Pyykkö I, Arroll MA, et al. Meniere's disease. Nat Rev Dis Primers. 2016;2:16028. doi:10.1038/nrdp.2016.28 PMID: 27170253

3. Havia M, Kentala E, Pyykkö I. Prevalence of Menière's disease in general population of Southern Finland. Otolaryngol Head Neck Surg. 2005;133(5):762-768. doi:10.1016/j.otohns.2005.06.015 PMID: 16274805

4. Havia M, Kentala E. Progression of symptoms of dizziness in Ménière's disease. Arch Otolaryngol Head Neck Surg. 2004;130(4):431-435. doi:10.1001/archotol.130.4.431 PMID: 15096426

5. Lopez-Escamez JA, Carey J, Chung WH, et al. Diagnostic criteria for Menière's disease. J Vestib Res. 2015;25(1):1-7. doi:10.3233/VES-150549 PMID: 25882471

6. NICE Clinical Knowledge Summaries. Ménière's Disease. cks.nice.org.uk (Accessed 2026-01-06)

Epidemiology and Natural History

7. Alexander TH, Harris JP. Current epidemiology of Meniere's syndrome. Otolaryngol Clin North Am. 2010;43(5):965-970. doi:10.1016/j.otc.2010.05.001 PMID: 20713235

8. Tyrrell JS, Whinney DJ, Ukoumunne OC, et al. Prevalence, associated factors, and comorbid conditions for Ménière's disease. Ear Hear. 2014;35(4):e162-e169. doi:10.1097/AUD.0000000000000041 PMID: 24732693

Pathophysiology

9. Arweiler-Harbeck D, Horsthemke B, Jahnke K, Hennies HC. Genetic aspects of familial Menière's disease. Otol Neurotol. 2011;32(4):695-700. doi:10.1097/MAO.0b013e318219f676 PMID: 21358445

10. Greco A, Gallo A, Fusconi M, et al. Meniere's disease might be an autoimmune condition? Autoimmun Rev. 2012;11(10):731-738. doi:10.1016/j.autrev.2012.01.004 PMID: 22306860

11. Radtke A, Lempert T, Gresty MA, et al. Migraine and Ménière's disease: is there a link? Neurology. 2002;59(11):1700-1704. doi:10.1212/01.wnl.0000036903.22461.39 PMID: 12473755

12. Derebery MJ. Allergic and immunologic features of Meniere's disease. Otolaryngol Clin North Am. 2011;44(3):655-666. doi:10.1016/j.otc.2011.03.004 PMID: 21621051

13. Merchant SN, Adams JC, Nadol JB Jr. Pathophysiology of Meniere's syndrome: are symptoms caused by endolymphatic hydrops? Otol Neurotol. 2005;26(1):74-81. doi:10.1097/00129492-200501000-00013 PMID: 15699723

Investigations

14. Schuknecht HF. Pathology of Menière's disease as it relates to the sac and tack procedures. Ann Otol Rhinol Laryngol. 1977;86(5 Pt 1):677-682. doi:10.1177/000348947708600516 PMID: 911148

15. Baloh RW, Jacobson K, Winder T. Drop attacks with Meniere's syndrome. Ann Neurol. 1990;28(3):384-387. doi:10.1002/ana.410280314 PMID: 2241119

16. National Institute for Health and Care Excellence. Hearing loss in adults: assessment and management. NICE guideline [NG98]. Published 2018. www.nice.org.uk/guidance/ng98

17. Nakashima T, Naganawa S, Sugiura M, et al. Visualization of endolymphatic hydrops in patients with Meniere's disease. Laryngoscope. 2007;117(3):415-420. doi:10.1097/MLG.0b013e31802c300c PMID: 17279053

Treatment Evidence

18. Murdin L, Hussain K, Schilder AGM. Betahistine for symptoms of vertigo. Cochrane Database Syst Rev. 2023;6(6):CD010696. doi:10.1002/14651858.CD010696.pub2 PMID: 36827524

19. Phillips JS, Westerberg B. Intratympanic steroids for Ménière's disease or syndrome. Cochrane Database Syst Rev. 2011;(7):CD008514. doi:10.1002/14651858.CD008514.pub2 PMID: 21735432

20. Pullens B, van Benthem PP. Intratympanic gentamicin for Ménière's disease or syndrome. Cochrane Database Syst Rev. 2011;(3):CD008234. doi:10.1002/14651858.CD008234.pub2 PMID: 21412917

21. Thomsen J, Bretlau P, Tos M, Johnsen NJ. Placebo effect in surgery for Menière's disease: a double-blind, placebo-controlled study on endolymphatic sac shunt surgery. Arch Otolaryngol. 1981;107(5):271-277. doi:10.1001/archotol.1981.00790410009002 PMID: 7013741

22. Syed MI, Ilan O, Nassar J, Rutka JA. Meniett device in Ménière's disease: a systematic review. J Otolaryngol Head Neck Surg. 2015;44:3. doi:10.1186/s40463-015-0055-9 PMID: 25890233

23. McDonnell MN, Hillier SL. Vestibular rehabilitation for unilateral peripheral vestibular dysfunction. Cochrane Database Syst Rev. 2015;1:CD005397. doi:10.1002/14651858.CD005397.pub4 PMID: 25581507

24. Formeister EJ, Rizk HG, Kohn MA, Sharon JD. The Epidemiology of Vestibular Migraine: A Population-based Survey Study. Otol Neurotol. 2018;39(8):1037-1044. doi:10.1097/MAO.0000000000001900 PMID: 30015730

---